BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two ...

As Modern Healthcare reports, CMS has relaxed supervision requirements for physical and occupational therapist assistants from “direct” to “general.” The change could help health systems manage ...

We signed three new platform license agreements during the quarter that ... During the quarter Genmab's GEN1057, an ...

Plan to announce initial clinical data for XMT-1660 at a company event by the end of 2024 Dose escalation advancing in Phase 1 clinical trial of XMT-2056 Conference call today at 8:00 a.m. ET CAMBRIDG ...

Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...

Collaborations: Mersana continues to advance its Johnson & Johnson and Merck KGaA ... on the development of novel ...

Sanofi gets rated buy today, agreeing with bullish ratings from the Wall Street and SA analysts' consensus. With a diverse ...

A study of Gila monster venom helped start the revolution in weight-loss drugs. But scientists think that’s just the ...

Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone mineral density, a ...

Germany-based BioNTech got into the space before the gold rush that was unleashed in September by the news that Akeso and ...

One investigation discussed during the call involves sales reps in China allegedly changing genetic testing results to secure reimbursement for Tagrisso.